EICHORPublic-registry site landscape for NCT03096392, “Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control”, a Diabetes Mellitus, Type 1 study sponsored by Diasome Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03096392 (registry record) |
| Study title | Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control |
| Official title | A Randomized Controlled Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro Alone to Further Improve Glycemic Control in Type 1 Diabetes Mellitus Subjects With Good Glycemic Control |
| Sponsor | Diasome Pharmaceuticals |
| Condition(s) | Diabetes Mellitus, Type 1 |
| Phase | PHASE2 |
| Listed sites | 5 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT03096392.
Eichor generates a preliminary site-risk snapshot for NCT03096392 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Diabetes Mellitus, Type 1 trials
More from Diasome Pharmaceuticals
← Eichor home · All tracked trials · Diabetes Mellitus, Type 1 studies · Weekly briefs
